The global cold pain therapy
market is witnessing considerable growth due to increasing
geriatric population, increasing healthcare expenditure and growing awareness about
cold pain therapy products. Moreover, increase in innovative product launches, increase
in road accidents and sport related injuries across the globe is supporting the
growth of the market. Based on product, the OTC based product segment lead the
global cold pain therapy market owing to its easy availability over the
counter, without any doctor prescription and ease of use. The popularity of
cold pain therapy products is due to presence of several pain relief products
in market. These products include creams, gels, ointments, sprays, cold packs,
rolls, cooling towels, motorized and non-motorized devices. Based on
application, the musculoskeletal disorders segment lead the global market due
to increasing cases of arthritis, osteoarthritis, joint pain and back pain across
the globe.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cold-pain-therapy-market/report-sample
Geographically, North America has been the largest market for cold
pain therapy, owing to increased awareness, and easy accessibility to advanced
technologies including motorized and non-motorized devices. Moreover, increasing
incidence of musculoskeletal conditions drives the market growth in the region.
The U.S. contributed largest revenue to the North American as well as global cold
pain therapy market. The presence of large pool of patients with back pain,
muscular pain and arthritis is the key driving factor of the U.S. cold pain
therapy market.
Explore report at: https://www.psmarketresearch.com/market-analysis/cold-pain-therapy-market
The key players operating in the global cold pain therapy market are Johnson
& Johnson, Sanofi, 3M Company, Hisamitsu Pharmaceutical Co., Inc., Rohto
Pharmaceutical Co., Ltd., Medline Industries, Inc., Beiersdorf AG, Breg, Inc., Ă–ssur
HF and DJO Finance LLC.
No comments:
Post a Comment